|
David M. Jablons, MD
Assistant Professor of Surgery Chief, General Thoracic Surgery/UCSF Mt. Zion Medical Center, San Francisco, CAPhone: (415) 885-3882 Dr. Jablons manages pleural mesothelioma with a radical pleurectomy/decortication and is researching other therapies.
Lary A. Robinson, MD
Director, Division of Cardiovascular and Thoracic Surgery Principal Thoracic Surgical Oncologist/H. Lee Moffitt Cancer Center and Research Institute, Tampa, FLPhone: (813) 972-8412 Dr. Robinson is a member of the multidisciplinary thoracic oncology group at H. Lee Moffitt Cancer Center where he evaluates and treats all stages of mesothelioma. He is also involved in clinical research programs for lung cancer and mesothelioma.
Robert N. Taub, MD
Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons/New York Presbyterian Hospital, New York, NYPhone: (212) 305-4076 Dr. Robert Taub is a medical oncologist and Director of the Connective Tissue Oncology Program at the Herbert Irving Comprehensive Cancer Center and involved in several ongoing multimodality studies of patients with pleural and peritoneal mesothelioma. The Center is located at the Columbia University College of Physicians and Surgeons.
Daniel Sterman, MD
Assistant Professor, Department of Medicine/University of Pennsylvania Medical Center, Philadelphia, PAPhone: (215) 614-0984 Dr. Sterman is the has published several articles on treatment and clinical trials for pleural mesothelioma.
Eric Vallieres, MD
Associate Professor of Surgery, Section of General Thoracic Surgery/University of Washington Medical Center, Seattle, WAPhone: (206) 598-4477 Dr. Vallieres employs a multidisciplinary approach to thoracic malignancies and related clinical trials. Dr. Vallieres co-authored an article on Induction Chemotherapy, Extra Pleural Pneumonectomy And Adjuvant Fast Neutron Radiationtherapy For Pleural Mesothelioma.
Stephen C. Yang, MD
Chief, Division of Thoracic Surgery/Associate Professor of Surgery and Oncology/Surgical Director, Lung Transplantation Program/Director, Thoracic Oncology Program/Johns Hopkins Medical Institutions, Baltimore, MD Phone: (410) 614-3891
Mark J. Krasna, MD
Chief, Division of Thoracic Surgery/University of Maryland School of Medicine; Director, Thoracic Oncology Program/University of Maryland Greenebaum Cancer Center, Baltimore, MDPhone: (410) 328-6366Dr. Krasna has been published extensively on the role of multidisciplinary treatment of lung and esophageal cancers. He is the Principal Investigator of a trimodality treatment protocol for pleural mesothelioma at the University of Maryland. He is also an investigator in intrapleural therapy for mesothelioma.
David H. Harpole, Jr., MD
Associate Professor of Surgery, Thoracic Oncology Program/AssistantProfessor of Pathology, Duke University Medical Center, Durham, NCPhone: (919) 668-8413
Harvey Pass, MD
Karmanos Cancer Institute, Detroit, MIPhone: (313) 745-8746 Dr. Pass is has been recognized around the world for the treatment of mesothelioma, with special expertise in the field of photodynamic therapy, a non-surgical approach.
Gregory P. Kalemkerian, MD
Co-Director of Thoracic Oncology/University of Michigan Comprehensive Cancer Center/Ann Arbor, MIPhone: (734) 936-5281 Dr. Kalemkerian is the director of the multidisciplinary thoracic oncology clinic at the University of Michigan Cancer Center, as well as collaborating with the thoracic oncology team at Karmanos Cancer Institute, to develop innovative clinical trials for mesothelioma patients.
Joseph S. Friedberg, MD
Chief of Thoracic Surgery/University of Pennsylvania at Presbyterian, Philadelphia, PAPhone: (215) 662-9195 Dr. Friedberg is the Principal Investigator on a trial of photodynamic therapy for pleural malignancies, and also on a trial combining Alimta/cisplatin, surgery and XRT.
David P. Mason, MD
Staff Surgeon, Department of Thoracic and Cardiovascular Surgery/Cleveland Clinic Foundation, Cleveland, OH Phone: (216) 444-4053 Dr. Mason supports the aggressive multimodality therapy for malignant mesothelioma. This includes extrapleural pneumonectomy, chemotherapy and radiation with Intensity Modulated Radiation Therapy (IMRT). Cleveland Clinic Foundation has a multidisciplinary Thoracic Oncology team with extensive experience and clinical trials in the management of malignant mesothelioma.
|
